Summary The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and progesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian cancers. EGFR was not significantly related to any of the clinicopathological parameters examined. In patients with stage II-IV disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031). Moreover, post-operative residual tumour showed an independent role in predicting chemotherapy response (P = 0.0007) and EGFR status showed a borderline significance (P = 0.052) in the multivariate analysis. No correlation between steroid hormone receptors and clinicopathological parameters was observed. Whereas a significant relationship was shown between EGFR positivity and a shorter overall survival (OS) (P = 0.0022) and progression-free survival (PFS) (P = Neal et al., 1991; Maurizi et al., 1992; Scambia et al., 1994). Moreover, in breast cancer EGFR expression seems to be a feature of hormone-independent aggressive clinical behaviour (Klijn et al., 1992) . Our previous study The membrane fraction and cytosol were prepared as described elsewhere . Briefly, tumour specimens were finely minced and homogenised in five volumes of ice-cold buffer consisting of 25 mM Tris, 1.5 mM EDTA, 5 mM sodium azide, 20% glycerol (TENG) plus 0.1 % monothioglycerol, by applying several intermittent bursts of an Ultra-Turrax homogeniser. The crude homogenate was centrifuged at 7000 g for 20 min at 0°C in order to separate nuclear fraction from the cytosol fraction. The supernatants were then centrifuged at 105 000 g for 75 min at 0°C, obtaining the membrane pellet and the cytosolic fraction.
Experimental evidence has shown that the EGF/EGFR system is involved in ovarian cancer cell growth regulation (Berchuck et al., 1990; Scambia et al., 1991) . At present, although EGFR expression has been widely demonstrated in ovarian cancer (Bauknecht et al., 1988; Battaglia et al., 1989; Berchuck et al., 1991; Stewart et al., 1992; van der Burg et al., 1993) , few studies have investigated the prognostic significance of EGFR (Bauknecht et al., 1988; Berchuck et al., 1991; van der Burg et al., 1993) . Some evidence does, however, demonstrate that high EGFR levels may be a negative prognostic indicator in many tumour types (Sainsbury et al., 1987; Neal et al., 1991; Maurizi et al., 1992; Scambia et al., 1994) . Moreover, in breast cancer EGFR expression seems to be a feature of hormone-independent aggressive clinical behaviour (Klijn et al., 1992) . Our previous study on a series of advanced ovarian carcinomas demonstrated higher EGFR levels in omental metastases than in primary tumours. We also reported that high EGFR levels were significantly associated with a greater risk of progression.
Data on the role of the expression of oestrogen receptor (ER) and progesterone receptor (PR) in ovarian cancer are discordant, although many authors have demonstrated that positivity for steroid hormone receptors is associated with a better prognosis (Harding et al., 1990; Rose et al., 1990; Sevelda et al., 1990; Slotman et al., 1990) . In this report the prognostic significance of EGFR, ER and PR was simultaneously analysed in a large prospective series of primary ovarian cancer patients observed for a long follow-up period.
Patients and methods
Our study included 117 stopped by the addition of 3 ml of TENG plus 0.1% bovine serum albumin. Pellets were obtained by centrifugation at 2000 g for 20 min at 0°C and counted in a gamma-counter for 1 min. Results were expressed as fmoles per mg of membrane protein (fmol mg-' protein).
In some cases Scatchard analysis of binding data was performed according to the previously described protocol 
Statistical analysis
The Wilcoxon rank sum non-parametric test was used to analyse the relationship between ER, PR and EGFR expression and clinicopathological characteristics.
In order to normalise the variance of error the receptor data were transformed into logl0 of data before performing
Pearson's correlation test (Altman, 1991).
All medians and life tables were computed using the product-limit estimate of Kaplan and Meier (1958) and the curves were examined by means of the log-rank test (Mantel, 1966) . Multivariate analysis was performed by the Coxproportional hazards model (Cox 1972) . Progression-free survival (PFS) and overall survival (OS) were calculated from the date of first surgery to the date of clinical or pathological progression or death. The median follow-up was 19 months (range 2-110 months).
Results
The distribution of EGFR levels in 117 primary ovarian tumours is shown in Figure 1 . EGFR levels were skewed towards the lower values and ranged from 0 to 14.8 fmol mg-' protein, with a median value of 1.5 fmol mg-' protein.
Sixty-three (54%) of the tumours were considered to be EGFR positive. (Table II) . PR expression was higher in patients with post-operative residual tumour <0.5 cm than in those with residual tumour > 0.5 cm (P = 0.01). Using data transformed into logarithms, a direct correlation was found between ER and PR expression (P = 0.017), while no correlation was observed between EGFR and ER/PR distribution (data not shown).
Eighty-six patients with stage II IV disease underwent second-look surgery after primary chemotherapy. Figure 2 shows the survival curves in relation to receptor status. A significant relationship was shown between EGFR positivity and a shorter OS (P = 0.0022) (Figure 2a) 
In our study EGFR status proved to be an important factor predicting response to chemotherapy in advanced ovarian tumours. In accordance with our data Berchuck et al. (1991) reported that 5 of 15 (33%) patients who showed complete response were EGFR negative, while only 8 of 49 (16%) patients who showed complete response were EGFR positive. Previously Bauknecht et al. (1986) reported that high intratumoral levels of an EGF-like substance were associated with poor response rate. There are few data on the possible link between EGFR expression and chemotherapy (1990) observed that high EGF/EGFR levels enhanced sensitivity to cisplatin in ovarian cancer cells. In this context it is also worth noting that the erbB-2 gene product, a member of the EGFR family, is in some way linked to chemosensitivity. Recent data showed that in ovarian cancer cells sensitivity to platinum compounds is related to erbB-2-pl85 expression (Pegram et al., 1983; Wolf et al., 1993) . Further studies using 'in vitro' models are needed in order to clarify the possible link of EGFR to mechanisms of tumour cell resistance to chemotherapy. Several studies have reported an inverse correlation between EGFR and ER/PR expression in breast cancer (Klijn et al., 1992) , which suggests that EGFR expression may identify tumours unresponsive to endocrine therapy. However, like' van der Burg et al. (1993) , we found no correlation between EGFR and steroid hormone receptors. This would suggest that in ovarian neoplasms steroid hormone and EGF receptor expression are independently regulated.
In our series neither ER nor PR expression showed any prognostic significance, even for different cut-off values. Nor did simultaneous expression of ER and PR, which is considered to imply good functionality of the steroid receptor machinery, show prognostic significance in these tumour subsets.
Whereas there is some evidence that ER expression does not play a prognostic role in ovarian cancer (Harding et al., 1990; Rose et al., 1990; Sevelda et al., 1990; Slotman et al., 1990) , there is no agreement as to PR expression. Although some authors have reported that PR expression is a favourable prognostic factor (Harding et al., 1990; Sevelda et al., 1990; Slotman et al., 1990; van der Burg et al., 1993) , we were not able to confirm this finding, in agreement with Rose et al. (1990) . Although the discrepancies may be due to different cut-off values and patient populations, it may be that PR positivity has only a minor prognostic impact since steroid hormones play a marginal role in onset and spread of ovarian cancer. This hypothesis is consistent with the finding that endocrine therapy is only slightly efficacious in the management of advanced ovarian cancer (Freedman et al., 1986; Schwartz et al., 1989) .
In conclusion our data indicate that high EGFR levels have a negative prognostic role in ovarian cancer patients. Therefore, drugs such as anti-EGFR monoclonal antibodies and the specific inhibitor of the EGFR tyrosine kinase, which have been shown to inhibit the growth of cancer cells 'in vitro ' and 'in vivo' (Kurachi et al., 1991; Moreshige et al., 1991; Fry et al., 1994; Schnurch et al., 1994) , may find use in ovarian cancer therapy.
